Cellectar Biosciences, Inc.
CLRB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001279704
No open-market purchases or sales by Cellectar Biosciences, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $9.08M in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Cellectar Biosciences, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 20 | 26 | +6 |
| Shares | 1.46M | 8.60M | +7.15M (+490.0%) |
| Value | $3.85M | $23.9M | +$20.0M (+519.6%) |
New holders (8)
Institutions that held Cellectar Biosciences, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Rosalind Advisors, Inc. | 2,005,658 | $5.56M | 4.65% |
| ADAR1 Capital Management, LLC | 1,378,082 | $3.82M | 1.71% |
| Nantahala Capital Management, LLC | 1,350,578 | $3.74M | 0.37% |
| Citadel Advisors LLC | 69,007 | $191.1K | 0.00% |
| GWM Advisors LLC | 21,013 | $77.5K | 0.00% |
| Coastal Bridge Advisors, LLC | 23,000 | $63.7K | 0.02% |
| Northern Trust Corp | 12,686 | $35.1K | 0.00% |
| Bank of America Corp | 16 | $44 | 0.00% |
Sold out (2)
Institutions that held Cellectar Biosciences, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Renaissance Technologies LLC | 21,690 | $57.0K |
| Wealth Enhancement Advisory Services, LLC | 12,000 | $31.7K |